In one of Switzerland's – and Europe's – largest biotech private equity deals for some time, Auris Medical AG landed CHF47.1 million (US$50.8 million) in a Series C funding from the two Sofinnovas, Sofinnova Ventures and Sofinnova Partners, to take forward its two lead drug candidates, AM-101 and AM-111, in acute tinnitus and acute inner ear hearing loss, respectively.
LONDON – Scientists are close to identifying new genes that may be linked to several eye diseases in humans, many of which cause blindness. The researchers are being guided by genes they have found in mice that, when absent, cause similar defects to those occurring in the eyes of humans who are affected by conditions such as one type of age-related macular degeneration (AMD).
S-TARget therapeutics GmbH, an Austrian start-up developing therapeutic vaccines for allergies, aims to close a €6 million (US$7.8 million) Series A funding round in the coming months.
MedDay raised €8 million (US$10.5 million) to take forward three drug development programs, two of which already have yielded promising data in small-scale human trials, in progressive forms of multiple sclerosis (MS) and in treatment-resistant forms of psychotic illness.
SHANGHAI – As the S&P 500, the Dow Jones Industrial Average and the Nasdaq Biotechnology Index close at record highs, one might think that respectable Chinese biopharmas on the New York Stock Exchange or Nasdaq would be well positioned to enjoy the benefits of such a robust stock market. In fact, many are cutting their ties.
Gene therapy start-up GenSight Biologics has raised €32 million (US$41 .6 million) in a Series A funding, hinting that following on from the first European regulatory approval of a gene therapy and with an increasing volume of positive clinical data, this iconic field is now de-risked in the eyes of venture capital investors.
Cancer specialist Activartis Biotech GmbH will present positive survival data from the Phase II trial of its dendritic cell therapy in treating glioblastoma at the American Association of Cancer Research (AACR) Wednesday, as it steps up efforts to find a partner to back a Phase III study.
Shares in ChronTech Pharma AB plunged as much as 40 percent during trading Tuesday on news that ChronVac-C, the company's therapeutic DNA vaccine for treating hepatitis C virus (HCV) infection, failed to attain efficacy in an interim analysis of data from a Phase II trial.
A fault in glucose metabolism lies at the heart of polycystic kidney disease, a common inherited condition that can cause end-stage renal failure by the age of 50, new research has shown.
RSS